{
    "clinical_study": {
        "@rank": "122516", 
        "arm_group": [
            {
                "arm_group_label": "TisssueGene-C", 
                "arm_group_type": "Experimental", 
                "description": "Single intra-articular injection to the damaged knee joint a dose of 1.8 x 10^7 cells"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single intra-articular injection to the damaged knee joint at the same volume"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether  TissueGene-C, an allogeneic human\n      chondrocytes expressing TGF-b1, is effective and safe  in patients with degenerative\n      arthritis."
        }, 
        "brief_title": "Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Degenerative Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Osteoarthritis"
            ]
        }, 
        "detailed_description": {
            "textblock": "TissueGene-C is a biological new drug which consists of normal chondrocytes and transduced\n      chondrocytes that express growth factors to regenerate the damaged cartilage tissues.\n\n      In the clinical trial Phase 2b, the investigators compared TissueGene-C to placebo during 6\n      - months trial with 54 outpatients who have had degenerative arthritis.   The outpatients\n      are assigned to TissueGene-C or placebo in 1:1 ratio, and will be monitored and recorded for\n      improving clinical symptoms, sports activities, and function of the knee, and for the\n      presence of adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients at least 18 years of age\n\n          -  Patients with IKDC score of 60 or below\n\n          -  Body Mass Index (BMI) between '18.5 - 30.0.'\n\n          -  Clinical diagnosis of degenerative arthritis\n\n          -  Kellgren & Lawrence Grade 2 or 3\n\n          -  ICRS of grade IV, defect < 6cm2\n\n          -  Female patients of childbearing potential must agree to practice adequate methods of\n             birth control to prevent pregnancy during the study\n\n          -  Patients who voluntarily agreed to enroll in the study and signed an informed consent\n             form\n\n        Exclusion Criteria:\n\n          -  Patients with abnormal hematology, serum chemistry, or urinalysis screening\n             laboratory results\n\n          -  Patients taking steroidal anti-inflammatory medications within 14 days of baseline\n             visit unless washed out\n\n          -  Patients with ongoing infectious disease, including HIV\n\n          -  Patients with clinically significant cardiovascular, renal, hepatic, endocrine\n             disease, cancer, Type I diabetes\n\n          -  Patients who are pregnant or currently breast-feeding children\n\n          -  Patients who were enrolled in any other clinical trials within the past 30 days\n\n          -  Patients who had been administered with oriental medicine, glucosamine and\n             chondroitin within 14 days of baseline visit\n\n          -  Patients who had been administered with immunosuppressants and antirheumatic drugs\n             within the past 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671072", 
            "org_study_id": "KS-TGC-01-2B"
        }, 
        "intervention": [
            {
                "arm_group_label": "TisssueGene-C", 
                "description": "Tissuege-C at 1.8 x 10^7 cells", 
                "intervention_name": "TisssueGene-C", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo control(Normal Saline)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chondrocyte cells", 
            "Osteoarthritis", 
            "Gene therapy"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gangnam-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "Asan Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National Univ. Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Placebo Controlled, Single-blind, Randomized, Multi-center Phase IIb Study to Determine the Efficacy and Safety of TissueGene-C, an Allogeneic Human Chondrocytes Expressing TGF-b1, in Patients With Degenerative Arthritis", 
        "overall_official": [
            {
                "affiliation": "Samsung Medical Center", 
                "last_name": "Chul Won Ha, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Seong Il Bin, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National Univ. Hospital", 
                "last_name": "Myung Chul Lee, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC)", 
            "measure": "Changes in IKDC Subjective Score.", 
            "safety_issue": "No", 
            "time_frame": "Week 0, 4, 12, 24 and 48"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671072"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities (WOMAC)", 
                "measure": "Changes in WOMAC scores.", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 4, 12, 24 and 48"
            }, 
            {
                "description": "Symptoms, pain and functionality of the knee joint will be evaluated via the Knee Injury and Osteoarthritis Outcome Score (KOOS)", 
                "measure": "Changes in KOOS scores.", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 4, 12, 24 and 48"
            }, 
            {
                "description": "Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS)", 
                "measure": "Changes in 100 mm-VAS.", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 4, 12, 24 and 48"
            }, 
            {
                "description": "Comparison of pre-procedure MRI scans to those obtained at pre-dosing and at months 6 and 12 following dosing by an independent radiographic reviewer.", 
                "measure": "MRI scan", 
                "safety_issue": "Yes", 
                "time_frame": "Week 0, 24 and 48"
            }
        ], 
        "source": "Kolon Life Science", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kolon Life Science", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}